Evolving Treatment Strategies for Lung Cancer

Lung cancer remains one of the leading causes of cancer-related morbidity and mortality worldwide. With the rapid development of molecular diagnostics, targeted therapies, immunotherapy, and novel drug platforms, the treatment landscape of lung cancer continues to evolve. Increasingly, treatment decisions are guided by tumor biology, molecular alterations, disease stage, prior therapies, and patterns of disease progression.

For patients with advanced non-small cell lung cancer (NSCLC), molecularly driven treatment has become an essential component of clinical management. In EGFR-mutated NSCLC, advances in targeted therapy have significantly improved disease control and survival. However, several clinical challenges remain, including treatment resistance and difficult-to-treat metastatic sites such as leptomeningeal carcinomatosis. Optimizing the integration and sequencing of available therapies is therefore an important consideration in improving outcomes for patients with advanced EGFR-mutated disease.

At the same time, the therapeutic landscape of small cell lung cancer (SCLC) is also changing. Immunotherapy has become an important component of treatment, while novel therapeutic targets are creating additional opportunities for patients with limited treatment options. In particular, DLL3 has emerged as a promising therapeutic target in SCLC, with new treatment approaches potentially changing the management of the disease across different stages and lines of therapy. The first-day program specifically addresses emerging immunotherapy strategies and DLL3-targeted therapy in SCLC.

In early-stage NSCLC, treatment is increasingly moving beyond surgery alone. Advances in biomarker testing and targeted therapies have expanded opportunities to reduce recurrence and improve long-term survival for patients with actionable genomic alterations, including EGFR mutations. These developments emphasize the importance of molecular testing not only in advanced disease but also in earlier stages of lung cancer.

Other oncogenic drivers, including HER2 alterations, ROS1 rearrangements, and KRAS G12C mutations, have also become increasingly relevant in precision treatment. The availability of newer targeted agents has broadened therapeutic options for these molecularly defined populations. For HER2-altered NSCLC, evolving targeted treatment strategies have created new considerations regarding patient selection and treatment sequencing. Similarly, advances in ROS1-directed therapies continue to expand the available treatment toolbox, while the development of KRAS G12C inhibitors has transformed a previously difficult-to-target molecular subgroup. These three areas form a major focus of the second-day program.

Overall, the two-day TASLC Lung Cancer Summit – Evolving Treatment Strategies for Lung Cancer highlights the continuing shift toward increasingly personalized lung cancer care. From the management of complex metastatic disease and advanced EGFR-mutated NSCLC to new approaches in SCLC and emerging targeted therapies for HER2, ROS1, and KRAS G12C alterations, the meeting provides an opportunity to review current evidence, discuss clinical challenges, and explore how new therapeutic strategies may be incorporated into everyday practice.